, Tracking Stock Market Picks
Enter Symbol:

up 147.45 %

JAZZ PHARMA INC (JAZZ) rated Buy with price target $195 by Stifel

Posted on: Wednesday,  Feb 26, 2014  8:25 AM ET by Stifel

Stifel rated Buy JAZZ PHARMA INC (NASDAQ: JAZZ) on 02/26/2014. Previously Stifel rated Buy JAZZ PHARMA INC (NASDAQ: JAZZ) on 05/31/2013.,
when the stock price was $69.01. Since then, JAZZ PHARMA INC has gained 147.46% as of 11/25/2015's recent price of $170.77.
If you would have followed the previous Stifel's recommendation on JAZZ, you would have gained 147.45% of your investment in 908 days.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/26/2014 8:25 AM Buy
162.06 195.00
as of 10/17/2014
1 Week up  2.28 %
1 Month down  -6.12 %
3 Months up  7.56 %
1 YTD up  20.38 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/31/2013 8:25 AM Buy
69.01 80.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy